Skip to main content

Leveraging a Real-World Clinicogenomic Database for Post-Sequencing Quality Assessment in Solid Tumor Comprehensive Genomic Profiling

15 Jul 2026

Reliable Genomic Profiling Performance Across Diverse Solid Tumor Types

Comprehensive genomic profiling (CGP) plays a critical role in identifying clinically relevant biomarkers that can guide precision oncology decisions. Ensuring consistent sequencing quality across diverse tumor samples is essential for delivering reliable results in routine clinical practice and drive translational research objectives.

This white paper highlights findings from a real-world evaluation of OmniSeq® INSIGHT, a formalin-fixed, paraffin-embedded (FFPE)-based comprehensive genomic profiling platform that integrates both DNA and RNA sequencing. The study assessed post-sequencing quality metrics across a broad range of solid tumor indications to evaluate platform performance and reliability in real-world clinical settings.

Key Takeaways

  • Consistent High-Quality DNA Sequencing Performance: Across all evaluated solid tumor types, DNA post-sequencing quality metrics demonstrated strong and reliable sequencing coverage, supporting accurate detection of clinically relevant genomic alterations.
  • Robust RNA Sequencing Metrics: RNA sequencing quality indicators, including read depth and on-target mapping performance, showed consistently high-quality results across diverse tumor samples.
  • Broad Applicability: The study demonstrated reliable performance of OmniSeq® INSIGHT using FFPE tumor samples across a wide variety of cancer types, reinforcing its value as a comprehensive genomic profiling solution in real-world settings.
  • Foundation for Future Clinical Expansion: Ongoing research will evaluate performance in more challenging specimen types, including fine needle aspirates and core needle biopsies, helping expand confidence in genomic testing across additional clinical scenarios.
about_omniseqr_insight.png


About OmniSeq® INSIGHT

OmniSeq® INSIGHT is a comprehensive genomic profiling platform that combines DNA and RNA sequencing from FFPE tumor tissue to detect:

  • Genomic alterations
  • Gene fusions
  • Microsatellite instability (MSI)
  • Tumor mutation burden (TMB)
  • Homologous recombination deficiency (HRD)

The integrated approach provides a comprehensive molecular view of solid tumors to support precision oncology decision-making.

Why This Research Matters

As comprehensive genomic profiling becomes increasingly important in oncology, laboratories and healthcare providers need confidence that testing platforms can consistently generate high-quality results across varied tumor types and real-world specimen conditions.

This study demonstrates the ability of a combined DNA and RNA sequencing workflow to maintain strong post-sequencing quality metrics, supporting dependable biomarker detection and clinical reporting.

Explore the complete methodology, quality assessment framework, sequencing performance metrics, and detailed study findings.

Download White Paper